The Chinese drug administration approved the supplementary application of China Meheco Group's (SHA:600056) unit, China National Pharmaceutical and Healthcare Industry, for nicorandil tablets after it passed the regulator's quality and efficacy consistency evaluation.
The pharmaceutical company invested 12.8 million yuan into the development of the drug, which is used to treat angina pectoris, according to a Shanghai Stock Exchange disclosure on Saturday.
Meheco's shares dropped 2% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments